ProFunds Biotechnology UltraSector Fund Investor Class (BIPIX)

61.02
Net Asset Value
-1.91%
1 Day
-2.32%
Year-to-Date
Overall Morningstar Rating
Trading--leveraged equity
Style or Category
No Load
Sales Expenses
1.45%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks daily investment results- before fees and expenses- that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. BiotechnologySM Index. The fund invests in securities and derivatives that the adviser believes- in combination- should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the biotechnology sector of the U.S. equity market. It is non-diversified.

Performance

1 month+0.56% 3 years-5.47%
3 months-11.46% 5 years+16.56%
1 year+15.63% Since inception+6.62%
Data through --

Peer Comparisonvs. Trading--leveraged equity

 BIPIXCategory
Performance 5-yr return+16.56%+16.48%
Expense ratio1.45%2.01%
Risk 5 year sharpe ratio0.60--
Net assets$244.6M$85.0M
Average market cap$58.7B--
Average P/E20.3--
Portfolio turnover14%14%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyProFunds
Fund manager & tenureMichael Neches / 4 Years
Minimal initial investment$15,000.00
Minimum IRA investment--

Holdings

U.S. stock77.67%
Cash22.30%
Other0.03%
Fixed income0.01%
International stock0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie15.49%
AMGN Amgen11.69%
GILD Gilead Sciences9.48%
CELG Celgene6.89%
BIIB Biogen6.37%
VRTX Vertex Pharmaceuticals Inc3.65%
ILMN Illumina Inc2.94%
REGN Regeneron Pharmaceuticals2.44%
ALXN Alexion Pharmaceuticals Inc2.31%
BMRN Biomarin Pharmaceutical Inc1.37%